Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
80 participants
INTERVENTIONAL
2015-02-28
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Cannabidiol and ∆-9-THC in Humans
NCT01180374
THC Memory & Reward Learning Pilot
NCT05116527
Effects of THC and CBD on Human Episodic Memory Function
NCT02291562
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I
NCT02709954
Cannabinoids, Neural Synchrony, and Information Processing
NCT00708994
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
THC
Active THC (0.0015mg/kg-0.03mg/kg) administered over 20 minutes.
THC
Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
Placebo
Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
Placebo
Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
THC
Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
Placebo
Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
THC
Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
Placebo
Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Exposed to cannabis at least once in their lifetime
Exclusion Criteria
* Positive pregnancy screen during screening
* Hearing deficits
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohini Ranganathan
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohini Ranganathan, M.D.
Role: PRINCIPAL_INVESTIGATOR
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Connecticut Healthcare System
West Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
No NIH funding
Identifier Type: OTHER
Identifier Source: secondary_id
1501015211
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.